Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq confirms SCNI’s shares now meet the $1.00 minimum bid standard, resolving a prior listing compliance issue.

Rhea-AI Summary

Scinai Immunotherapeutics (SCNI) has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.

Nasdaq notified the company on September 21, 2026 that the minimum bid price matter is closed after Scinai’s ADSs posted a closing bid of at least $1.00 per share for 19 consecutive business days from August 21 through September 17, 2026. The earlier deficiency arose when the ADSs traded below $1.00 for 30 consecutive business days prior to a March 12, 2026 notice from Nasdaq Staff.

Positive

• Nasdaq confirms SCNI has regained $1.00 minimum bid price compliance
• 19 consecutive business days with closing bid at or above $1.00 per share

Negative

• Prior deficiency notice on March 12, 2026 for ADSs below $1.00 for 30 consecutive business days

Argus 15 min delay

+10.90% vs previous close $1.73 last price 1237.1x rel. volume Open Argus

Details

Market reaction after Nasdaq compliance update: SCNI +10.90%

+35.5% Peak Tracked

-2.4% Trough Tracked

$1.57 $2.13 Day Range

$1.17M Market Cap

Following this news, SCNI has gained 10.90%, reflecting a significant positive market reaction. Argus tracked a peak move of +35.5% during the session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner has triggered 33 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.73. Trading volume is exceptionally heavy at 1237.1x the average, suggesting very strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The pre-publication SCNI close was down 3.7%; the momentum scanner showed only CDT down 1.15%, so th...

Analysis

The pre-publication SCNI close was down 3.7%; the momentum scanner showed only CDT down 1.15%, so the supplied data did not show a broad same-direction peer move for this compliance notice.

Key Figures

Minimum bid price: $1.00 per share Compliance period: 19 consecutive business days Prior deficiency period: 30 consecutive business days

Minimum bid price

$1.00 per share

Nasdaq Listing Rule 5550(a)(2)

Compliance period

19 consecutive business days

August 21, 2026 through September 17, 2026

Prior deficiency period

30 consecutive business days

Period preceding Nasdaq's March 12, 2026 notification

Key Terms

american depositary shares, cdmo

2 terms

american depositary shares financial

"Company's American Depositary Shares ("ADSs") had failed"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

cdmo technical

"revenue-generating contract development and manufacturing organization ("CDMO")"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed

JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced that it has received written notification from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed.

On March 12, 2026, Nasdaq Staff notified Scinai that the Company's American Depositary Shares ("ADSs") had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days. In its September 18, 2026 compliance letter, Nasdaq stated that for the 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai's ADSs was at $1.00 per share or greater. Accordingly, Nasdaq determined that Scinai had regained compliance with Listing Rule 5550(a)(2).

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai," said Amir Reichman, Chief Executive Officer of Scinai. "We appreciate Nasdaq Staff's review and constructive engagement throughout the process. With this matter resolved, our focus remains on commercial execution at Scinai Biopharma Services and disciplined advancement of our NanoAb programs."

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. The Company is developing its NanoAb platform through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.

Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit www.scinai.com.

Company Contacts

Business Development | +972 8 930 2529 | bd@scinai.com

Investor Relations, Allele Capital Partners | +1 (561) 388-8178 | BDeBeer@allelecapital.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. These include statements regarding the Company's continued commercial execution, CDMO growth and customer programs, NanoAb development and the Company's ability to maintain compliance with Nasdaq listing requirements.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Such risks include the Company's ability to secure sufficient financing or non-dilutive funding on satisfactory terms or at all; increase CDMO revenues and execute customer programs; maintain research and license arrangements; generate supportive preclinical or clinical data; obtain regulatory approvals; secure development partners; maintain compliance with Nasdaq listing requirements; and respond to competition and market, regulatory, geopolitical and economic conditions. Additional information appears in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on April 1, 2026. Forward-looking statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise them.

View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302883956.html

SOURCE SCINAI IMMUNOTHERAPEUTICS LTD